A Clinical Study of NLY01 in Patient's With | Clinical Research Studies Listing

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Recruiting

30 years - 80 years

All

Phase 2

4 participants needed

1 Location

Brief description of study

This is a study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in Parkinson's disease and is being developed as a potential treatment for neurodegenerative disorders.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Parkinson's Disease
Age: 30 years - 80 years
Gender: All

Male or Female, Age 30-80, Diagnosed with Parkinson's disease

Updated on 04 Aug 2024. Study ID: 842594

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Brief description of study

Eligibility of study

Find a site

Interested in the study